When Context Is Hard to Come By: External Comparators and How to Use Them

被引:11
作者
Mack, Christina [1 ]
Christian, Jennifer [1 ]
Brinkley, Emma [1 ]
Warren, Edward J. [1 ]
Hall, Marni [2 ]
Dreyer, Nancy [3 ]
机构
[1] IQVIA Real World & Analyt Solut, 4820 Emperor Blvd, Durham, NC 27703 USA
[2] IQVIA Real World & Analyt Solut, Rockville, MD USA
[3] IQVIA Real World & Analyt Solut, Cambridge, MA USA
关键词
historical controls; synthetic controls; real-world evidence; real-world data; benchmark;
D O I
10.1177/2168479019878672
中图分类号
R-058 [];
学科分类号
摘要
External comparators, also referred to as historical or synthetic controls, present transformational opportunities for broad context and insights alongside clinical research results. The recent confluence of access to quality real-world data (RWD), advanced epidemiologic methods, and legislative directives to regulators for expanded use of RWD is increasing interest in real-world external comparators, opening the door to achieve broader generalizability and learn more, faster. In this less standardized area of research, tailored scientific methodology must be applied for external comparators to accomplish clinical development objectives. Here, we describe methodological considerations for design and illustrate how RWD comparators have been used for regulatory and reimbursement decisions.
引用
收藏
页数:7
相关论文
共 25 条
[1]   A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review [J].
Beaver, Julia A. ;
Howie, Lynn J. ;
Pelosof, Lorraine ;
Kim, Tamy ;
Liu, Jinzhong ;
Goldberg, Kirsten B. ;
Sridhara, Rajeshwari ;
Blumenthal, Gideon M. ;
Farrell, Ann T. ;
Keegan, Patricia ;
Pazdur, Richard ;
Kluetz, Paul G. .
JAMA ONCOLOGY, 2018, 4 (06) :849-856
[2]   Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe [J].
Becker, Juergen C. ;
Lorenz, Eva ;
Ugurel, Selma ;
Eigentler, Thomas K. ;
Kiecker, Felix ;
Pfoehler, Claudia ;
Kellner, Ivonne ;
Meier, Friedegund ;
Kaehler, Katharina ;
Mohr, Peter ;
Berking, Carola ;
Haas, Gabriele ;
Helwig, Christoph ;
Oksen, Dina ;
Schadendorf, Dirk ;
Mahnkel, Lisa ;
Bharmal, Murtuza .
ONCOTARGET, 2017, 8 (45) :79731-79741
[3]  
Broaderick JM., 2017, AVELUMAB APPROVED EU
[4]   Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe [J].
Cave, Alison ;
Kurz, Xavier ;
Arlett, Peter .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) :36-39
[5]  
Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), AD DES CLIN TRIALS D
[6]  
Christian J, 2018, POSTAUTHORIZATION SA, P150
[7]   Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA [J].
Cowey, C. Lance ;
Mahnke, Lisa ;
Espirito, Janet ;
Helwig, Christoph ;
Oksen, Dina ;
Bharmal, Murtuza .
FUTURE ONCOLOGY, 2017, 13 (19) :1699-1710
[8]   Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable [J].
Dreyer, Nancy A. .
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (03) :362-368
[9]  
FDA, 2018, Framework for FDA's Real-World Evidence Program
[10]   Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia [J].
Goekbuget, N. ;
Kelsh, M. ;
Chia, V. ;
Advani, A. ;
Bassan, R. ;
Dombret, H. ;
Doubek, M. ;
Fielding, A. K. ;
Giebel, S. ;
Haddad, V. ;
Hoelzer, D. ;
Holland, C. ;
Ifrah, N. ;
Katz, A. ;
Maniar, T. ;
Martinelli, G. ;
Morgades, M. ;
O'Brien, S. ;
Ribera, J-M ;
Rowe, J. M. ;
Stein, A. ;
Topp, M. ;
Wadleigh, M. ;
Kantarjian, H. .
BLOOD CANCER JOURNAL, 2016, 6 :e473-e473